AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

Earnings are out

NNVC · AMEX · Biotechnology

NanoViricides (NNVC)

Develops host-mimetic antiviral candidates for multiple viral diseases.

$1.17

Pre-market−0.01 (−0.85%)

At close$1.18(−2.48%)

Watchlist

In millions of USD, except per-share figures

In millions	Q4 FY23Jun 2023	Q1 FY24Sep 2023	Q2 FY24Dec 2023	Q3 FY24Mar 2024	Q4 FY24Jun 2024	Q1 FY25Sep 2024	Q2 FY25Dec 2024	Q3 FY25Mar 2025	Q4 FY25Jun 2025	Q1 FY26Sep 2025	Q2 FY26Dec 2025	Q3 FY26Mar 2026
Cost of revenue	0	0	0	0	0	0	0	0	0	0	0	0
Gross profit	0	0	0	0	0	0	0	0	0	0	0	0
	4	2	2	2	2	3	2	2	2	2	2	2
Research & development	3	1	2	1	1	2	1	1	1	1	1	1,285,942
	1	1	1	1	1	1	1	1	1	1	1	744,276
General & administrative	1	1	1	1	1	1	1	1	1	1	1	744,276
Other expenses	0	0	0	0	0	0	0	0	0	0	0	−2,030,216
Operating income	−4	−2	−2	−2	−2	−3	−2	−2	−2	−2	−2	−2
	0	0	0	0	0	0	0	0	0	0	0	0
Interest income	0	0	0	0	0	0	0	0	0	0	0	0
Interest expense	0	0	0	0	0	0	0	0	0	0	0	0
Other non-operating income	0	0	0	0	0	0	0	0	0	0	0	0
Income before tax	−4	−2	−2	−2	−2	−3	−2	−2	−2	−2	−2	−2
Net income from continuing operations	−4	−2	−2	−2	−2	−3	−2	−2	−2	−2	−2	−2
Net income	−4	−2	−2	−2	−2	−3	−2	−2	−2	−2	−2	−2
EPS, basic	−$0.31	−$0.17	−$0.18	−$0.16	−$0.20	−$0.23	−$0.14	−$0.14	−$0.13	−$0.10	−$0.11	−$0.09
EPS, diluted	−$0.31	−$0.17	−$0.18	−$0.16	−$0.20	−$0.23	−$0.14	−$0.14	−$0.13	−$0.10	−$0.11	−$0.09
Weighted average shares, basic	12	12	12	12	12	14	15	16	17	17	20	22
Weighted average shares, diluted	12	12	12	12	12	14	15	16	17	17	20	22
EBITDA	−3	−2	−2	−2	−2	−3	−2	−2	−2	−2	−2	−2
Depreciation & amortization	0	0	0	0	0	0	0	0	0	0	0	0
EBIT	−4	−2	−2	−2	−2	−3	−2	−2	−2	−2	−2	−2